| Literature DB >> 30352587 |
Ya-Fei Xu1, Ying-Qing Li2, Na Liu2, Qing-Mei He2, Xin-Ran Tang2, Xin Wen2, Xiao-Jing Yang2, Ying Sun2, Jun Ma3, Ling-Long Tang4.
Abstract
BACKGROUND: Alternative polyadenylation (APA) is a widespread phenomenon in the posttranscriptional regulation of gene expression that generates mRNAs with alternative 3'-untranslated regions (3'UTRs). APA contributes to the pathogenesis of various diseases, including cancer. However, the potential role of APA in the development of nasopharyngeal carcinoma (NPC) remains largely unknown.Entities:
Keywords: Alternative polyadenylation; Genome-wide profiling; High-throughput sequencing; Nasopharyngeal carcinoma
Mesh:
Year: 2018 PMID: 30352587 PMCID: PMC6198351 DOI: 10.1186/s12929-018-0477-6
Source DB: PubMed Journal: J Biomed Sci ISSN: 1021-7770 Impact factor: 8.410
Summary of the SAPAS data from Illumina HiSeq 2000 sequencing
| NPC | NNET | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NPC1 | NPC2 | NPC3 | NPC4 | NPC5 | NPC6 | NNET1 | NNET2 | NNET3 | NNET4 | NNET5 | NNET6 | |
| Raw reads(M*) | 26.08 | 23.81 | 24.48 | 25.29 | 25.14 | 20.99 | 25.94 | 23.91 | 25.77 | 24.87 | 26.97 | 24.56 |
| Clean reads(M) | 25.90 | 23.54 | 24.06 | 24.94 | 24.94 | 20.83 | 25.77 | 23.59 | 25.33 | 24.70 | 26.64 | 24.42 |
| Mapped to genome(M) | 21.73 | 19.75 | 20.02 | 21.06 | 21.39 | 17.45 | 21.28 | 19.49 | 21.09 | 19.53 | 19.46 | 21.10 |
| Uniquely mapped to genome(M) | 17.02 | 16.42 | 16.11 | 16.82 | 17.29 | 14.33 | 17.45 | 15.87 | 17.75 | 16.17 | 15.72 | 17.48 |
| Mapped to nuclear genome(M) | 13.32 | 14.63 | 13.11 | 13.02 | 14.69 | 13.34 | 15.21 | 14.45 | 15.71 | 14.57 | 13.92 | 14.76 |
| Passed Internal Priming filter(M) | 11.51 | 9.83 | 10.18 | 10.30 | 12.68 | 11.36 | 12.00 | 11.47 | 10.01 | 12.50 | 12.06 | 12.36 |
| Genes sampled by reads(10 K) | 1.78 | 1.89 | 1.88 | 1.90 | 1.80 | 1.83 | 1.86 | 1.88 | 1.91 | 1.88 | 1.73 | 1.87 |
| Poly(A) sites(10 K) | 13.70 | 29.99 | 17.36 | 19.04 | 13.82 | 12.50 | 22.75 | 18.14 | 36.03 | 16.28 | 12.45 | 14.90 |
| Known poly(A) sites sampled(10 K) | 2.75 | 2.90 | 2.89 | 2.89 | 2.82 | 2.87 | 2.84 | 2.92 | 2.86 | 2.97 | 2.67 | 2.90 |
| Putative novel poly(A) sites(10 K) | 10.95 | 27.09 | 14.47 | 16.15 | 11.00 | 9.63 | 19.91 | 15.21 | 33.17 | 13.31 | 9.78 | 12.01 |
| Genes sampled by poly(A) sites(10 K) | 1.62 | 1.72 | 1.71 | 1.73 | 1.63 | 1.66 | 1.73 | 1.72 | 1.73 | 1.72 | 1.53 | 1.72 |
Fig. 1The characteristics of the SAPAS data. a The genomic locations of reads that specifically aligned to the nuclear genome after internal priming filtering. b The histogram of the number of reads for UCSC canonical genes. c The distribution of numbers of poly(A) sites per gene. d The genomic locations of poly(A) sites for UCSC canonical genes
Genes with APA site switching between NPC and NNET tissues using a pair-wise case-control analysis
| Pairs | 3’UTR shortened genes | 3’UTR lengthened genes | Combined |
|---|---|---|---|
| NPC1 vs. NNET1 | 104 | 372 | 476 |
| NPC1 vs. NNET2 | 179 | 192 | 371 |
| NPC1 vs. NNET3 | 144 | 247 | 391 |
| NPC1 vs. NNET4 | 58 | 242 | 300 |
| NPC1 vs. NNET5 | 99 | 446 | 545 |
| NPC1 vs. NNET6 | 51 | 123 | 174 |
| NPC2 vs. NNET1 | 55 | 85 | 140 |
| NPC2 vs. NNET2 | 91 | 13 | 104 |
| NPC2 vs. NNET3 | 108 | 38 | 146 |
| NPC2 vs. NNET4 | 100 | 85 | 185 |
| NPC2 vs. NNET5 | 123 | 234 | 357 |
| NPC2 vs. NNET6 | 184 | 106 | 290 |
| NPC3 vs. NNET1 | 63 | 143 | 206 |
| NPC3 vs. NNET2 | 104 | 23 | 127 |
| NPC3 vs. NNET3 | 51 | 26 | 77 |
| NPC3 vs. NNET4 | 79 | 103 | 182 |
| NPC3 vs. NNET5 | 68 | 178 | 246 |
| NPC3 vs. NNET6 | 149 | 111 | 260 |
| NPC4 vs. NNET1 | 62 | 167 | 229 |
| NPC4 vs. NNET2 | 210 | 104 | 314 |
| NPC4 vs. NNET3 | 136 | 115 | 251 |
| NPC4 vs. NNET4 | 158 | 236 | 394 |
| NPC4 vs. NNET5 | 156 | 355 | 511 |
| NPC4 vs. NNET6 | 133 | 125 | 258 |
| NPC5 vs. NNET1 | 158 | 377 | 535 |
| NPC5 vs. NNET2 | 193 | 116 | 309 |
| NPC5 vs. NNET3 | 150 | 153 | 303 |
| NPC5 vs. NNET4 | 55 | 112 | 167 |
| NPC5 vs. NNET5 | 107 | 286 | 393 |
| NPC5 vs. NNET6 | 66 | 82 | 148 |
| NPC6 vs. NNET1 | 102 | 202 | 304 |
| NPC6 vs. NNET2 | 137 | 24 | 161 |
| NPC6 vs. NNET3 | 147 | 99 | 246 |
| NPC6 vs. NNET4 | 53 | 58 | 111 |
| NPC6 vs. NNET5 | 90 | 172 | 262 |
| NPC6 vs. NNET6 | 139 | 76 | 215 |
Enrichment of genes with tandemed 3’UTR isoforms involved in various GO functional categories
| GO category | Count | ||
|---|---|---|---|
| GOTERM_BP_FAT | Regulation of cell migration | 9 | 0.0004 |
| GOTERM_BP_FAT | Regulation of locomotion | 9 | 0.001 |
| GOTERM_BP_FAT | Regulation of cell motion | 9 | 0.001 |
| GOTERM_BP_FAT | Macromolecule catabolic process | 19 | 0.0015 |
| GOTERM_BP_FAT | Protein catabolic process | 16 | 0.0024 |
| GOTERM_BP_FAT | Proteolysis | 20 | 0.015 |
| GOTERM_MF_FAT | Small conjugating protein ligase activity | 7 | 0.0052 |
| GOTERM_MF_FAT | Acid-amino acid ligase activity | 7 | 0.013 |
| GOTERM_MF_FAT | Ubiquitin-protein ligase activity | 6 | 0.013 |
| KEGG_PATHWAY | Ubiquitin mediated proteolysis | 6 | 0.022 |
| KEGG_PATHWAY | Lysosome | 5 | 0.048 |
| KEGG_PATHWAY | Colorectal cancer | 5 | 0.017 |
| KEGG_PATHWAY | Renal cell carcinoma | 4 | 0.049 |
Nine genes enriched in GO terms associated with cell migration
| UCSC ID | Gene Symbol | Gene Name | |
|---|---|---|---|
| uc002aqj.2 | SMAD3a | SMAD family member 3 | 0.086 |
| uc002wnw.2 | JAG1a | jagged 1 (Alagille syndrome) | −0.351 |
| uc003jva.2 | Pikr1 | phosphoinositide-3-kinase, regulatory subunit 1 (alpha) | 0.0007 |
| uc003pek.2 | Ptp4a1 | protein tyrosine phosphatase type IVA, member 1 | 0.929 |
| uc003spw.2 | Rac1 | ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1) | 0.175 |
| uc009ygq.2 | RRAS2 | related RAS viral (r-ras) oncogene homolog 2; similar to related RAS viral (r-ras) oncogene homolog 2 | − 0.564 |
| uc002ita.2 | Spag9 | sperm associated antigen 9 | 0.411 |
| uc003uww.2 | TRIP6 | thyroid hormone receptor interactor 6 | 0.182 |
| uc003yrx.2 | TRIB1 | tribbles homolog 1 (Drosophila) | −0.206 |
agenes selected for quantitative RT-PCR validation
r-value: a positive value of r indicates a longer tandem 3’UTR in NPC, and vice versa
Fig. 2Validation of 3’UTR switching in 16 NPC and NNET samples with quantitative RT-PCR. a JAG1; (B) IRF1; (c) EGLN1; (d) TIMP3; (e) WDR5; (f) SMAD3; (g) XRCC5; (h) FNDC3B. Proximal/Distal indicates the expression ratio of the shortened 3’UTR to the lengthened 3’UTR